07.10.20

Kodiak Sciences Announces New Longer-Term Data from Ongoing Phase 1b Study of KSI-301 in Patients With Retinal Diseases

Source: Kodiak Sciences

07.07.20

Outlook Therapeutics Completes Patient Enrollment for NORSE 2 Study of Lytenava

Source: Outlook Therapeutics

06.26.20

The FDA Does Not Approve Allergan’s Wet AMD Drug Candidate Abicipar Pegol

Source: Eyewire News

06.24.20

AsclepiX Therapeutics Announces $35 Million Series A Financing

Source: AsclepiX Therapeutics

05.27.20

Port Delivery System With Ranibizumab Shows Positive Phase 3 Results in Wet AMD

Source: Genentech

05.18.20

Samsung Bioepis Announces 24-Week Interim Results From a Phase 3 Trial of Ranibizumab Biosimilar

Source: Samsung Bioepis

05.05.20

Adverum Biotechnologies Reports Positive Interim Data of ADVM-022 Intravitreal Gene Therapy for Wet AMD

Source: Adverum Biotechnologies

05.05.20

Studies Yield Mixed Findings for Investigational Drug Abicipar in Wet AMD

Source: Reuters

04.22.20

Regenxbio Announces Additional Positive Long-Term and Interim Phase 1/2a Trial Update for RGX-314 for the Treatment of Wet AMD

Source: Regenxbio

03.17.20

Ribomic Enters License Agreement with AJU Pharma for RBM-007 in AMD

Source: Ribomic

View more stories